Friday, July 12, 2019

Professor Jarosław Dastych, leading scientist and Founder CEO of Proteon Pharmaceuticals discusses his precision biology based solution for sustainable poultry farming

Professor Jarosław Dastych, leading scientist and Founder CEO of Proteon Pharmaceuticals discusses his precision biology based solution for sustainable poultry farming

The technology uses ‘bacteriophages’ as a preventative antibacterial solution to improve animal and human health

The sustainable alternative to bacterial disease prevention promises to have long term benefits for human health and environment


MumbaiRising demand for meat and eggs and a resultant turn towards intensive poultry production has in recent decades given rise to a number of health and environmental concerns that pose a challenge to the poultry industry. Bacterial disease causes huge economic losses while resulting in environmental waste and threat to human health. The solution lies in innovation to promote safe and sustainable animal farming.

It is estimated that Campylobacter and Salmonella infections that are rampant in poultry together account for 9 in 10 reported cases of bacteria-related food poisonings globally. On the other hand, excessive use of veterinary drugs, feed additives and anti-microbials that are currently used to treat animals and prevent diseases can have major long term implications on human health and the environment.

As one of the largest producers of poultry and eggs, India has also faced concerns over safety of its chicken stock and eggs. #IndiaForHealthyChicken is a powerful initiative that promotes the need for cultivating healthy birds for the larger good of human beings and the environment. 

To address the challenges emanating from current farming practices, Proteon Pharmaceuticals, a Poland-based innovative biotechnology company has pioneered a revolutionary new approach to support healthy growth of chicken and other livestock. The new approach provides a sustainable tool for bacterial disease prevention. It also supports healthier poultry birds with improved performance.



































Professor Jarosław Dastych, the Founder CEO of Proteon Pharmaceuticals, is a leading scientist, an author of over 40 international publications and a co-author of 4 biotechnology-related patents. His research interests range from immunology, toxicology and molecular biology to the development of novel diagnostic tools and bacteriophage-based or related treatment of disease. Prof Dastych was in Mumbai today to discuss his revolutionary approach to breeding healthy poultry birds and the widespread benefits it will have on human and environmental health. The revolutionary new approach to bacterial control uses naturally occurring microorganisms ‘bacteriophages’ to eliminate pathogenic bacteria without causing any harm to the microbiome or gut flora of the birds. By promoting health growth of birds, this significantly reduces the need for use of antibiotics. “Bacteriophages a.k.a phages are microorganisms that are a natural element of our environment. Phages are everywhere, i.e. on human hands, skin, in the animal gut and in the soil. They are the oldest and most numerous organisms on Earth – and have been protecting humans and animals from bacteria for the last 3.5 billion years. Because lytic phages eliminate only their selected bacteria (they are unable to interact with animal or human cells), they are completely safe to birds or humans and they eliminate the bacteria without any damage to the microbiome, whose diversity is crucial for efficient feed conversion and immunity,” explained Professor Jarosław Dastych.

Proteon’s innovation has been possible thanks to the development of an advanced phage-technology platform. The platform uses precision biology, genomics, bioinformatics and molecular biology to identify, test and select appropriate bacteriophages. Using Artificial intelligence, the technology then selects phages that can be developed for industrial production which are then delivered to the industrial farming environment in the form of feed additives.

“The word bacteriophage actually means ‘bacteria eater’. These phages destroy their host cells through a natural process without interacting with human or animal cells. Neither do they contaminate the soil or the waters, nor do they leave residue in the meat. This makes them environmentally sustainable and healthy as well. Because they do not damage the microbiome, they help support growing naturally more healthy animals, which require fewer artificial and/or damaging solutions to prevent bacterial contamination,” adds Dr Bhushan Bhavsar, Managing Director - Vetphage Pharmaceuticals Pvt. Ltd. Vetphage Pharmaceuticals is a subsidiary Company of Proteon Pharmaceuticals SA. Vetphage handles all operations for the APAC region. As its MD, Dr Bhavsar is leading the movement#IndiaForHealthyChicken from the front.

The products containing a cocktail of bacteriophage are 100% natural and biodegradable. They are used as feed additives for poultry and aquaculture, while the company is developing further solutions for pig and cattle farming. They help to reduce pathogenic bacteria without side effects, without leaving any residue and without creating antibiotic resistant strains of bacteria.

India is the third-largest egg producer in the world after China and the USA and the fourth-largest chicken producer in the world after China, Brazil and the USA. In India, the per capita consumption of eggs has gone up from 30 eggs per annum to 68 eggs per annum, and that of chicken from 400 gms per annum, to 2.5 kg per annum between 2012 and 2017.


ABOUT PROFESSOR JAROSŁAW DASTYCH: Prof. Jarosław Dastych received his PhD in Medical Biology from the Medical University of Łódź in 1991 and started his scientific carrier at the Polish Academy of Sciences in Łódź, Poland. For several years he worked at the US National Institute of Health (NIH) in Bethesda, USA. In 2000 Prof. Dastych established the first research laboratory at the newly created International Institute of Molecular and Cell Biology in Warsaw. In 2005 Prof. Dastych created Proteon Pharmaceuticals, a Polish biotechnological company that belongs to the world leaders using bacteriophages (natural organisms that destroy pathogenic bacteria) in industrial animal breeding.

ABOUT PROTEON PHARMACEUTICALS & VETPHAGE PHARMACEUTICALS Proteon Pharmaceuticals S.A. is a Polish biotechnological company that is a leader among companies that use bacteriophages in industrial scale. The company developed and produces a new generation of natural antibacterial products used to protect health of livestock, i.e. poultry, cattle, fish without affecting human health. Proteon Pharmaceuticals has globally-unique solutions, starting with the development of bacteriophage products, through initiating and running research works (in own R&D Centre), to commercial testing of solutions and their industrial production, marketing, sales and distribution.
The products are used to protect animal health against pathogenic bacteria: BAFASAL® and BAFASAL+G®used in poultry farming prevent Salmonella infections and BAFADOR® is used in fish farming to fight against most common deadly pathogens. The company also develops new products for poultry and fish farming and solutions for pig and cattle farming. Proteon Pharmaceuticals also offers microbiology services in farming diagnostics, production environment monitoring and veterinary autovaccines.
Vetphage Pharmaceuticals is a subsidiary of Proteon Pharmaceuticals Group based in Mumbai. Its main focus is to market high quality, effective and innovative veterinary bacteriophage products, created by Proteon, available at affordable cost to poultry industry in India and neighboring countries. Vetphage currently offers 3 products – BAFASAL®, BAFASAL+G® (for poultry) and BAFADOR® (for aquaculture).

No comments:

Post a Comment

GIVE REVIEW ABOUT OUR UPDATE OR REQUEST

Adroit Industries (India) Limited IPO Opens on Wednesday, September 23, 2026 Total Offer Size- Up to 1,12,47, 000 Equity Shares of face value of ₹10 each Fresh Issue Size - Up to 98,97,000 Equity Shares OFS size - Up to 13,50,000 Equity Shares Total Size - ₹ 150.71 Crore (At Upper Price Band) Price Band - ₹ 126 - ₹ 134 per share Lot Size – 111 Equity Shares Mumbai, September 21, 2026 - Adroit Industries (India) Limited is a vertically integrated manufacturer of propeller shafts and torque-transmission components with over four decades of operational experience, serving automotive, primarily commercial vehicles, and non-automotive applications, including defence and emergency services, heavy equipment and off-highway machinery and industrial equipment across more than 32 countries, proposes to open its Initial Public Offering on Wednesday, September 23, 2026 aiming to raise ₹ 150.71 Crores (At Upper Price Band), with shares to be listed on the BSE & NSE. The offer size is up to 1,12,47,000 Equity Shares with a face value of ₹10 each with a price band of ₹126 - ₹134 Per Share. Equity Share Allocation QIB Portion – Not more than 50.00% of the Offer Non-Institutional Investors - Not less than 15.00% of the Offer Retail Individual Investors - Not less than 35.00% of the Offer The net proceeds from the IPO will be utilized for funding capital expenditure by the company towards procurement of machinery and equipment for enhancement of operations at the Dewas Facility and transportation vehicles for movement of goods between the manufacturing facilities, investment in its subsidiary Adroit Driveshafts Private Limited for capital expenditure towards machinery and equipment at the Pithampur Facility and transportation vehicles for movement of goods between the manufacturing facilities, investment in the subsidiary for repayment or pre-payment, in full or in part, of certain outstanding borrowings availed by it, and general corporate purposes. The anchor bidding is on Tuesday, September 22, 2026. The offer will open on Wednesday, September 23, 2026 and will close on Friday, September 25, 2026. The Book Running Lead Manager to the Offer is Choice Capital Advisors Private Limited and the Registrar is Bigshare Services Private Limited. Mr. Saurabh Sangla, Chairman and Managing Director of Adroit Industries (India) Limited “expressed, The upcoming IPO marks a new phase for the Company. Over the years we have built vertically integrated capabilities spanning forging, precision machining, heat treatment, assembly, balancing and testing, and expanded our portfolio to over 5,000 SKUs of driveline components supplied to customers in more than 32 countries. Going forward, our focus will be on strengthening capacity across our manufacturing facilities, improving operational efficiency, deepening engagement with the Distributors, OEMs and Tier-1 customers across our export and domestic markets and broadening our automotive and non-automotive applications. The IPO will support our plans as we continue to strengthen the business and pursue long-term growth.” Mr. Ratiraj Tibrewal, Director of Choice Capital Advisors Private Limited said, “Adroit Industries (India) Limited has built an export-led driveline business over four decades, with vertically integrated manufacturing and a diversified customer base across automotive and non-automotive applications. The upcoming IPO marks an important step in the Company’s journey as it enters the public markets. We believe the Company’s integrated manufacturing capabilities, long-standing customer relationships and expanding product portfolio provide a foundation for its next phase of growth. We are pleased to be associated with Adroit Industries (India) Limited as it takes this step towards becoming a publicly listed company.” About Adroit Industries (India) Limited Adroit Industries (India) Limited is a vertically integrated manufacturer and supplier of propeller shafts – also known as drive shafts or cardan shafts – and related torque-transmission components. Its portfolio spans over 5,000 SKUs of driveline components, including propeller shaft assemblies, yokes, shafts, companion flanges, universal joints and accessories, supplied to automotive applications, largely commercial vehicles and SUVs, and to non-automotive applications spanning defence and emergency services, heavy equipment and off-highway machinery and industrial equipment. The Company operates three manufacturing facilities in Madhya Pradesh – Dewas Facility i.e for die making and forging processes, Pithampur Facility for machining and assembly, operated by its subsidiary Adroit Driveshafts Private Limited, and Sanwer Road Facility for certain finishing operations– with end-to-end in-house capabilities covering forging, precision machining, heat treatment, assembly, balancing and testing. The facility is certified under IATF 16949, ISO 9001, ISO 14001 and ISO 45001. With operations commencing in 1966, the Company has evolved into an export-led driveline components manufacturer, with 95.39% of Fiscal 2026 product sales derived from outside India across more than 32 countries, supported by a Canadian subsidiary for North American customer engagement, and serving 185 customers in Fiscal 2026 through distributors, Tier-1 driveline component suppliers and OEMs. In FY26, The Company achieved a Revenue from operations of ₹1,399.43 million, EBITDA of ₹387.10 million & PAT of ₹261.58 million. Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Adroit Industries (India) Limited IPO Opens on Wednesday, September 23, 2026 Total Offer Size- Up to 1,12,47, 000 Equity Shares of face valu...